Safety Analysis of Four Randomized Controlled Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Mantle.

Slides:

Advertisements

Similar presentations

CyclinD1/CyclinD3 Ratio by Real-Time PCR Improves Specificity for the Diagnosis of Mantle Cell Lymphoma Carol D. Jones, Katherine H. Darnell, Roger A.

Advertisements

Risk of Atrial Fibrillation and Bleeding Diathesis Associated With Ibrutinib Treatment: A Systematic Review and Pooled Analysis of Four Randomized Controlled.

Incidence and Risk of Cardiac Events in Patients With Previously Treated Multiple Myeloma Versus Matched Patients Without Multiple Myeloma: An Observational,

Large-Cell Transformation of Mycosis Fungoides Occurring at the Site of Previously Treated Cutaneous B-Cell Lymphoma Jennifer L. Herrmann, Naveed Sami

Clinical Lymphoma, Myeloma and Leukemia

Pleural Effusion in Dasatinib-Treated Patients With Chronic Myeloid Leukemia in Chronic Phase: Identification and Management Jorge E. Cortes, Carlos.

VcR-CVAD Induction Chemotherapy Followed by Maintenance Rituximab Produces Durable Remissions in Mantle Cell Lymphoma: A Wisconsin Oncology Network Study

Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib by Preetesh Jain, Michael Keating, William Wierda, Zeev Estrov, Alessandra.

Effects of Bosutinib Treatment on Renal Function in Patients With Philadelphia Chromosome-Positive Leukemias Jorge E. Cortes, Carlo Gambacorti-Passerini,

The Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765) Promotes High Response Rate, Durable Remissions, and Is Tolerable in Treatment Naïve.

Mortality and Vascular Events Among Elderly Patients With Chronic Myeloid Leukemia: A Retrospective Analysis of Linked SEER-Medicare Data Kathleen Lang,

Incidence and Risk of Cardiac Events in Patients With Previously Treated Multiple Myeloma Versus Matched Patients Without Multiple Myeloma: An Observational,

The Epidemiology and Clinical Associations of Stroke in Patients With Acute Myeloid Leukemia: A Review of 10,972 Admissions From the 2012 National Inpatient.

Efficacy of Standard Dose R-CHOP Alternating With R-HDAC Followed by Autologous Hematopoietic Cell Transplantation as Initial Therapy of Mantle Cell Lymphoma,

M. Jensenius, P. -E. Fournier, K. B. Helium, L. Wesslén, G. Caruso, T

Residual Cancer Lymphocytes in Patients With Chronic Lymphocytic Leukemia After Therapy Show Increased Expression of Surface Antigen CD52 Detected Using.

Tait D. Shanafelt, MD, Timothy G. Call, MD Mayo Clinic Proceedings

Prognostic Nomogram for Overall Survival in Extranodal Natural Killer/T-Cell Lymphoma Patients Kaiguo Li, Ruyue Wang, Shiting Huang, Xinbin Pan, Hongmin.

Treatment With JAK Inhibitors in Myelofibrosis Patients Nullifies the Prognostic Impact of Unfavorable Cytogenetics Vincent T. Ma, Philip S. Boonstra,

Patterns of Infection in Patients With Myelodysplastic Syndromes and Acute Myeloid Leukemia Receiving Azacitidine as Salvage Therapy. Implications for.

Limited Utility of Surveillance Imaging for Detecting Disease Relapse in Patients With Non-Hodgkin Lymphoma in First Complete Remission Quoc Truong,

Differences in Quality of Life Between Bendamustine-Rituximab and R-CHOP/R-CVP in Patients With Previously Untreated Advanced Indolent Non-Hodgkin Lymphoma.

A Phase II Trial of Rituximab Combined With Pegfilgrastim in Patients With Indolent B- cell Non-Hodgkin Lymphoma Pallawi Torka, Priyank Patel, Wei Tan,

Improvement in Parameters of Hematologic and Immunologic Function and Patient Well-being in the Phase III RESONATE Study of Ibrutinib Versus Ofatumumab.

Consolidative Radiotherapy to Residual Masses After Chemotherapy Is Associated With Improved Outcome in Diffuse Large B-Cell Lymphoma. A Retrospective,

A Comparison of Clofarabine-based (GCLAC) and Cladribine-based (CLAG) Salvage Chemotherapy for Relapsed/Refractory AML Benyam Muluneh, Kaitlyn Buhlinger,

Subepithelial Corneal Immunoglobulin Deposition as a Manifestation of Multiple Myeloma: A Case Report and Literature Review Trent P. Wang, Steven G.

Ibrutinib Dose Adherence and Therapeutic Efficacy in Non-Hodgkin Lymphoma: A Single-Center Experience AnnaLynn M. Williams, Andrea M. Baran, Carla Casulo,

Prognostic Testing Patterns and Outcomes of Chronic Lymphocytic Leukemia Patients Stratified by Fluorescence In Situ Hybridization/Cytogenetics: A Real-world.

Effects of Ruxolitinib Treatment on Metabolic and Nutritional Parameters in Patients With Myelofibrosis From COMFORT-I Ruben A. Mesa, Srdan Verstovsek,

Systematic Literature Review of Treatment Options and Clinical Outcomes for Patients With Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic.

Health-Related Quality of Life of Patients With Multiple Myeloma Treated in Routine Clinical Practice in France Nicolas Despiégel, Chantal Touboul, Alain.

Alemtuzumab and CHOP Chemotherapy for the Treatment of Aggressive Histology Peripheral T Cell Lymphomas: A Multi-Center Phase I Study Rena Buckstein,

Discrimination of novel bunyavirus infection using routine laboratory test Q.-B. Lu, Z.-D. Yang, L.-Y. Wang, S.-L. Qin, N. Cui, H.-Y. Wang, H. Li, K.

Efficacy and Toxicity of Idarubicin Versus High-dose Daunorubicin for Induction Chemotherapy in Adult Acute Myeloid Leukemia: A Systematic Review and.

Elotuzumab in Combination with Lenalidomide and Dexamethasone for Treatment- resistant Immunoglobulin Light Chain Amyloidosis With Multiple Myeloma Shumaila.

Genetic Mutations in B-Acute Lymphoblastic Leukemia Among African American and European American Children Amit Reddy, Ingrid Espinoza, Dana Cole, Jason.

An Open-label, Phase II Trial of Entospletinib (GS-9973), a Selective Spleen Tyrosine Kinase Inhibitor, in Diffuse Large B-cell Lymphoma John M. Burke,

Jeffrey C. Fink, Glenn M. Chertow Kidney International

Hemophagocytic Lymphohistiocytosis in a Patient With Multiple Myeloma

ZOHé: A Prospective Study of the Use of Biosimilar Filgrastim Zarzio in Clinical Practice in Patients Treated With Chemotherapy for Lymphoid Malignancies

Clinical and Disease Characteristics From REVEAL at Time of Enrollment (Baseline): Prospective Observational Study of Patients With Polycythemia Vera.

Single-Agent Liposomal All-Trans-Retinoic Acid as Initial Therapy for Acute Promyelocytic Leukemia: 13-Year Follow-Up Data Preetesh Jain, Hagop Kantarjian,

Practical Measures of Clinical Benefit With Ruxolitinib Therapy: An Exploratory Analysis of COMFORT-I Carole B. Miller, Rami S. Komrokji, Ruben A. Mesa,

Edmund G. Lowrie Kidney International

Clinical Efficacy of Romidepsin in Tumor Stage and Folliculotropic Mycosis Fungoides Francine Foss, Madeleine Duvic, Adam Lerner, Joel Waksman, Sean Whittaker

Madeliene Parrott, Simon Rule, Michael Kelleher, Jayne Wilson

Rituximab-Based Chemoimmunotherapy Prolongs Survival of Patients With Chronic Lymphocytic Leukemia Independently of the Time of Administration Julio.

Predictive and Prognostic Markers in Adults With Acute Myeloid Leukemia: A Single- Institution Experience Bolanle Gbadamosi, Daniel Ezekwudo, Sanjog Bastola,

Generic Imatinib Therapy Among Jordanians: An Observational Assessment of Efficacy and Safety in Routine Clinical Practice Abdalla Awidi, Salah Abbasi,

Effectiveness and Safety of Therapeutic Regimens for Elderly Patients With Acute Myeloid Leukemia: A Systematic Literature Review Jill A. Bell, Aaron.

Modified VR-CAP, Alternating With Rituximab and High-dose Cytarabine: An Effective Pre-transplant Induction Regimen for Mantle Cell Lymphoma Stephen.

Large-Cell Transformation of Mycosis Fungoides Occurring at the Site of Previously Treated Cutaneous B-Cell Lymphoma Jennifer L. Herrmann, Naveed Sami

Challenges in Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN)

Sharon Seth, MD, David A. Khan, MD

An Evidence-based Review of Anti-CD20 Antibody-containing Regimens for the Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia,

Clinical Management of Patients Receiving Tyrosine Kinase Inhibitors for Advanced Renal Cell Carcinoma Jan Roigas European Urology Supplements Volume.

Phase II Study of Vincristine Sulfate Liposome Injection (Marqibo) and Rituximab for Patients With Relapsed and Refractory Diffuse Large B-Cell Lymphoma.

Evaluating the Impact of a Switch to Nilotinib on Imatinib-Related Chronic Low-Grade Adverse Events in Patients With CML-CP: The ENRICH Study Jorge E.

Residual Cancer Lymphocytes in Patients With Chronic Lymphocytic Leukemia After Therapy Show Increased Expression of Surface Antigen CD52 Detected Using.

Clinical Lymphoma, Myeloma and Leukemia

Pure Erythroid Leukemia Presenting in a HIV-Positive Patient

Mantle Cell Involvement of the Spleen

Michael Y. Choi, George F. Widhopf, Christina C. N

Adverse Outcomes: Why Bad Things Happen to Good People

Volume 163, Issue 2, (October 2015)

Exercise in Individuals With CKD: A Focus Group Study Exploring Patient Attitudes, Motivations, and Barriers to Exercise Jessica Kendrick, Michael Ritchie,

11q Deletion (del11q) Is Not a Prognostic Factor for Adverse Outcomes for Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Autologous Stem Cell Transplantation for POEMS Syndrome

Ruxolitinib for Myelofibrosis–An Update of Its Clinical Effects

Presentation transcript:

Safety Analysis of Four Randomized Controlled Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Mantle Cell Lymphoma Susan O'Brien, Peter Hillmen, Steven Coutre, Paul M. Barr, Graeme Fraser, Alessandra Tedeschi, Jan A. Burger, Marie-Sarah Dilhuydy, Georg Hess, Carol Moreno, Paula Cramer, Emily Liu, Stephen Chang, Jessica Vermeulen, Lori Styles, Angela Howes, Danelle F. James, Kalpesh Patel, Thorsten Graef, Rudolph Valentino Clinical Lymphoma, Myeloma and Leukemia Volume 18, Issue 10, Pages 648-657.e15 (October 2018) DOI: 10.1016/j.clml.2018.06.016 Copyright © 2018 The Authors Terms and Conditions

Supplemental Figure 1 Prevalence of Most Common (≥ 10%) All-grade Adverse Events With Ibrutinib Over Time Abbreviation: URTI = upper respiratory tract infection. Clinical Lymphoma, Myeloma and Leukemia 2018 18, 648-657.e15DOI: (10.1016/j.clml.2018.06.016) Copyright © 2018 The Authors Terms and Conditions

Supplemental Figure 2 Prevalence of Most Common (≥ 3%) Grade 3/4 Adverse Events With Ibrutinib Over Time Clinical Lymphoma, Myeloma and Leukemia 2018 18, 648-657.e15DOI: (10.1016/j.clml.2018.06.016) Copyright © 2018 The Authors Terms and Conditions

Supplemental Figure 3 (A) Mean Platelet, (B) Hemoglobin, and (C) Neutrophil Counts Over Time Abbreviations: ANC = absolute neutrophil count; SEM = standard error of the mean. Clinical Lymphoma, Myeloma and Leukemia 2018 18, 648-657.e15DOI: (10.1016/j.clml.2018.06.016) Copyright © 2018 The Authors Terms and Conditions

Supplemental Figure 4 Liver Values Over Time in Studies (A) 1112, (B) 1115, (C) CLL3001, and (D) MCL3001 Abbreviations: ALT = alanine transaminase; AST = aspartate transaminase; SEM = standard error of the mean. Clinical Lymphoma, Myeloma and Leukemia 2018 18, 648-657.e15DOI: (10.1016/j.clml.2018.06.016) Copyright © 2018 The Authors Terms and Conditions

Supplemental Figure 4 Liver Values Over Time in Studies (A) 1112, (B) 1115, (C) CLL3001, and (D) MCL3001 Abbreviations: ALT = alanine transaminase; AST = aspartate transaminase; SEM = standard error of the mean. Clinical Lymphoma, Myeloma and Leukemia 2018 18, 648-657.e15DOI: (10.1016/j.clml.2018.06.016) Copyright © 2018 The Authors Terms and Conditions